Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer
- 4 April 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Genitourinary Cancer
- Vol. 19 (5), e326-e333
- https://doi.org/10.1016/j.clgc.2021.03.022
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyThe New England Journal of Medicine, 2014
- No improvement noted in overall or cause‐specific survival for men presenting with metastatic prostate cancer over a 20‐year periodCancer, 2013
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2013
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyThe New England Journal of Medicine, 2013
- Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate CancerClinical Medicine Insights: Oncology, 2012
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2010
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerThe New England Journal of Medicine, 2004
- A convenient approximation of life expectancy (the “DEALE”): II. Use in medical decision-makingThe American Journal of Medicine, 1982
- A convenient approximation of life expectancy (the “DEALE”): I. validation of the methodThe American Journal of Medicine, 1982